Poprzedni Temat

Kliniczne aspekty urazów i chorób kości: część 1 i 2 | Clinical Aspects of Skeletal Injuries and Diseases: part 1 and 2

Tooltip .tooltip { position: relative; cursor: pointer; text-decoration: none; border-bottom: 1px dashed rgba(0, 0, 0, 0.6); } .tooltip::before { content: attr(data-tooltip); position: absolute; top: -40px; /* Trochę niżej nad słowem */ left: 50%; /* Wyśrodkowanie */ transform: translateX(-50%); background-color: rgba(255, 255, 255, 0.9); color: #333; padding: 6px 12px; border-radius: 8px; white-space: nowrap; opacity: 0; visibility: hidden; transition: opacity 0.3s ease, visibility 0.3s ease; font-family: ‘Arial’, sans-serif; font-size: 14px; box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1); z-index: 10; } .tooltip:hover::before { opacity: 1; visibility: visible; } document.addEventListener(‘DOMContentLoaded’, function () { const wordsToTooltip = { “Paget’s Disease of Bone”: “Choroba Pageta kości”, “chronic bone disorder”: “Przewlekła choroba kości”, “bone remodeling processes”: “Procesy przebudowy kości”, “enlarged bones”: “Powiększone kości”, “weakened bones”: “Osłabione kości”, “misshapen bones”: “Zdeformowane kości”, “genetic factors”: “Czynniki genetyczne”, “environmental factors”: “Czynniki środowiskowe”, “viral infections”: “Infekcje wirusowe”, “paramyxovirus”: “Paramyksowirus”, “osteoclasts”: “Osteoklasty”, “bone resorption”: “Resorpcja kości”, “osteoblasts”: “Osteoblasty”, “structurally weak bone”: “Strukturalnie słaba kość”, “asymptomatic”: “Bezobjawowy”, “Bone pain”: “Ból kości”, “pelvis”: “Miednica”, “spine”: “Kręgosłup”, “legs”: “Nogi”, “Bone deformities”: “Deformacje kości”, “skull”: “Czaszka”, “long bones”: “Kości długie”, “Fractures”: “Złamania”, “Hearing loss”: “Utrata słuchu”, “auditory nerves”: “Nerwy słuchowe”, “Joint pain”: “Ból stawów”, “arthritis”: “Zapalenie stawów”, “weight-bearing joints”: “Stawy nośne”, “hips”: “Biodra”, “knees”: “Kolana”, “X-rays”: “Rentgen (RTG)”, “Bone scan”: “Scyntygrafia kości”, “Alkaline phosphatase (ALP)”: “Fosfataza alkaliczna (ALP)”, “active disease”: “Aktywna choroba”, “bone turnover”: “Przebudowa kości”, “Bisphosphonates”: “Bisfosfoniany”, “Calcitonin”: “Kalcytonina”, “Pain management”: “Leczenie bólu”, “Analgesics”: “Środki przeciwbólowe”, “anti-inflammatory drugs”: “Leki przeciwzapalne”, “Surgery”: “Chirurgia”, “fractures correction”: “Korekcja złamań”, “severe deformities”: “Poważne deformacje”, “joint replacement”: “Wymiana stawu”, “advanced cases”: “Zaawansowane przypadki”, “Osteoarthritis”: “Choroba zwyrodnieniowa stawów”, “Heart failure”: “Niewydolność serca”, “increased blood supply”: “Zwiększone ukrwienie”, “localized disease”: “Choroba miejscowa”, “bisphosphonate therapy”: “Terapia bisfosfonianami”, “bone cancer (osteosarcoma)”: “Rak kości (kostniakomięsak)”, “Osteogenesis Imperfecta”: “Wrodzona łamliwość kości”, “Brittle Bone Disease”: “Choroba łamliwych kości”, “genetic disorder”: “Choroba genetyczna”, “fragile bones”: “Kruchliwe kości”, “type I collagen”: “Kolagen typu I”, “bone structure”: “Struktura kości”, “Type I”: “Typ I”, “Type II”: “Typ II”, “Type III”: “Typ III”, “Type IV”: “Typ IV”, “bone fragility”: “Kruchość kości”, “respiratory issues”: “Problemy oddechowe”, “bone deformities”: “Deformacje kości”, “bowing of limbs”: “Wygięcie kończyn”, “Blue sclera”: “Niebieska twardówka”, “ear bone malformations”: “Deformacje kostek słuchowych”, “Short stature”: “Niski wzrost”, “connective tissue abnormalities”: “Nieprawidłowości tkanki łącznej”, “Genetic testing”: “Badania genetyczne”, “Bone density testing”: “Badanie gęstości kości”, “fracture risk”: “Ryzyko złamań”, “Physical therapy”: “Fizjoterapia”, “rodding surgery”: “Chirurgia wstawiania prętów”, “stabilize long bones”: “Stabilizacja kości długich”, “Hearing aids”: “Aparaty słuchowe”, “chronic pain”: “Przewlekły ból”, “reduced mobility”: “Ograniczona ruchomość”, “Scoliosis”: “Skolioza”, “Spinal deformities”: “Deformacje kręgosłupa”, “rib fractures”: “Złamania żeber”, “Type I prognosis”: “Rokowanie dla typu I”, “Type II prognosis”: “Rokowanie dla typu II”, “Type III prognosis”: “Rokowanie dla typu III”, “Type IV prognosis”: “Rokowanie dla typu IV”, “Rheumatoid Arthritis (RA)”: “Reumatoidalne zapalenie stawów (RZS)”, “autoimmune disorder”: “Choroba autoimmunologiczna”, “synovium”: “Błona maziowa”, “joint destruction”: “Zniszczenie stawów”, “Bone erosion”: “Erozja kości”, “Fatigue”: “Zmęczenie”, “joint deformities”: “Deformacje stawów”, “anti-CCP antibodies”: “Przeciwciała anty-CCP”, “early bone erosion”: “Wczesna erozja kości”, “synovitis”: “Zapalenie błony maziowej”, “disease-modifying antirheumatic drugs (DMARDs)”: “Leki modyfikujące przebieg choroby reumatycznej (DMARDs)”, “Biologic therapies”: “Terapie biologiczne”, “joint replacement surgery”: “Operacja wymiany stawu”, “Fibrous Dysplasia”: “Dysplazja włóknista”, “fibrous tissue”: “Tkanka włóknista”, “GNAS gene”: “Gen GNAS”, “mutation”: “Mutacja”, “monostotic disease”: “Choroba jednoszkieletowa”, “polyostotic disease”: “Choroba wieloszkieletowa”, “ground glass appearance”: “Obraz matowego szkła”, “Bone biopsy”: “Biopsja kości”, “fibrous tissue diagnosis”: “Rozpoznanie tkanki włóknistej”, “NSAIDs”: “NLPZ (niesteroidowe leki przeciwzapalne)”, “Malignant transformation”: “Transformacja złośliwa”, “osteosarcoma progression”: “Postęp kostniakomięsaka”, “Hyperparathyroidism”: “Nadczynność przytarczyc”, “Parathyroid hormone (PTH)”: “Hormon przytarczyc (PTH)”, “osteitis fibrosa cystica”: “Zapalenie włóknisto-torbielowate kości”, “Primary hyperparathyroidism”: “Pierwotna nadczynność przytarczyc”, “Secondary hyperparathyroidism”: “Wtórna nadczynność przytarczyc”, “chronic kidney disease”: “Przewlekła choroba nerek”, “Serum calcium”: “Wapń w surowicy”, “PTH levels”: “Poziom PTH”, “calcimimetics”: “Kalcymimetyki”, “Primary Bone Tumors”: “Guzy pierwotne kości”, “benign bone tumors”: “Łagodne guzy kości”, “malignant bone tumors”: “Złośliwe guzy kości”, “Osteosarcoma”: “Kostniakomięsak”, “Chondrosarcoma”: “Chrzęstniakomięsak”, “Ewing Sarcoma”: “Mięsak Ewinga”, “osteochondroma”: “Kostniakochrzęstniak”, “giant cell tumor”: “Guz olbrzymiokomórkowy”, “enchondroma”: “Chrzęstniak wewnętrzny”, “Li-Fraumeni syndrome”: “Zespół Li-Fraumeni”, “retinoblastoma”: “Siatkówczak”, “Metastasis”: “Przerzuty”, “Secondary Bone Tumors”: “Wtórne guzy kości”, “Breast Cancer Metastasis”: “Przerzuty raka piersi”, “osteolytic lesions”: “Zmiany osteolityczne”, “Prostate Cancer Metastasis”: “Przerzuty raka prostaty”, “osteoblastic lesions”: “Zmiany osteoblastyczne”, “Lung Cancer Metastasis”: “Przerzuty raka płuc”, “Kidney Cancer Metastasis”: “Przerzuty raka nerki”, “Renal cell carcinoma”: “Rak jasnokomórkowy nerki”, “Hypercalcemia”: “Hiperkalcemia”, “Bone scan”: “Scyntygrafia kości”, “CT scans”: “Tomografia komputerowa (CT)”, “MRI scans”: “Rezonans magnetyczny (MRI)”, “Palliative care”: “Opieka paliatywna”, “Spinal cord compression”: “Ucisk rdzenia kręgowego” }; // Normalize keys in the dictionary const normalizedWordsToTooltip = {}; for (const [key, value] of Object.entries(wordsToTooltip)) { const cleanedKey = key.replace(/(.*?)/g, ”).trim(); // Remove anything in parentheses normalizedWordsToTooltip[cleanedKey.toLowerCase()] = value; } function processNode(node) { if (node.nodeType === Node.TEXT_NODE && node.nodeValue.trim()) { let content = node.nodeValue; // Regex to match only the main words (ignores parentheses) const regex = new RegExp( `\b(${Object.keys(normalizedWordsToTooltip).join(‘|’)})\b`, ‘gi’ ); if (regex.test(content)) { const wrapper = document.createElement(‘span’); wrapper.innerHTML = content.replace(regex, (match) => { const tooltip = normalizedWordsToTooltip[match.toLowerCase().trim()]; return `${match}`; }); node.replaceWith(wrapper); } } else if (node.nodeType === Node.ELEMENT_NODE) { Array.from(node.childNodes).forEach(processNode); } } document.querySelectorAll(‘body *:not(script):not(style)’).forEach((element) => { Array.from(element.childNodes).forEach(processNode); }); });

Paget’s Disease of Bone

Paget’s disease is a chronic bone disorder characterized by the disruption of normal bone remodeling processes, resulting in enlarged, weakened, and misshapen bones.

Causes and Pathophysiology

The exact cause of Paget’s disease is unclear, though genetic and environmental factors may play a role. Some theories suggest viral infections (e.g., paramyxovirus) may trigger the disease in genetically susceptible individuals. The disease primarily affects osteoclasts, causing abnormal bone resorption and subsequent disorganized bone formation by osteoblasts, leading to structurally weak bone.

Clinical Manifestations

Paget’s disease can be asymptomatic, but when symptoms do occur, they may include:

  • Bone pain: Often the first symptom, most commonly in the pelvis, spine, or legs.
  • Bone deformities: Enlarged or misshapen bones, particularly in the skull, spine, and long bones.
  • Fractures: The affected bones become weak and prone to fractures.
  • Hearing loss: Due to involvement of the skull and compression of auditory nerves.
  • Joint pain and arthritis: Especially in weight-bearing joints like hips and knees.

Diagnosis

  • X-rays: Show enlarged, thickened bones with areas of increased density.
  • Bone scan: Helps identify all areas of the body affected by the disease.
  • Alkaline phosphatase (ALP) blood test: Elevated in patients with active disease due to increased bone turnover.

Treatment

  • Bisphosphonates: First-line treatment to inhibit osteoclast activity and reduce bone turnover.
  • Calcitonin: An alternative therapy for patients who cannot tolerate bisphosphonates.
  • Pain management: Analgesics or anti-inflammatory drugs for bone and joint pain.
  • Surgery: Required for correcting fractures, severe deformities, or joint replacement in advanced cases.

Complications

  • Fractures: Weakened bones are more susceptible to breaks.
  • Osteoarthritis: Paget’s can lead to joint damage due to misalignment or bone overgrowth.
  • Hearing loss: Often permanent if auditory nerves are damaged.
  • Heart failure: In rare cases, due to the increased blood supply required by affected bones.

Prognosis for Paget’s Disease of Bone

  • Mild Cases: Patients with localized and mild disease often have a good prognosis, especially when the condition is detected early and managed effectively with bisphosphonate therapy. Many individuals remain asymptomatic or experience only minor symptoms.
  • Progressive Disease: In more advanced cases, complications such as bone deformities, fractures, and arthritis may develop, impacting quality of life.
  • Rare Complications: There is a small risk (less than 1%) of developing bone cancer (osteosarcoma) in advanced stages of Paget’s disease.

Osteogenesis Imperfecta (Brittle Bone Disease)

Osteogenesis Imperfecta (OI) is a genetic disorder causing fragile bones that break easily, often from minimal trauma. It is caused by defects in the production of type I collagen, a major component of bone structure.

Types of Osteogenesis Imperfecta

Type Description
Type IThe mildest form, characterized by bone fragility, normal height, and minimal deformity.
Type IIThe most severe form, often leading to death shortly after birth due to respiratory issues and multiple fractures.
Type IIISevere form with significant bone deformities and fractures at birth.
Type IVIntermediate severity with moderate bone deformity and frequent fractures.

Clinical Manifestations

OI symptoms depend on the type but generally include:

  • Frequent fractures: Even with minimal or no trauma.
  • Bone deformities: Particularly in more severe forms (e.g., bowing of limbs).
  • Blue sclera: A bluish tint to the whites of the eyes.
  • Hearing loss: Occurs in adulthood due to ear bone malformations.
  • Short stature: Particularly in more severe cases.
  • Loose joints: Due to connective tissue abnormalities.

Diagnosis

  • Genetic testing: Confirms the diagnosis by identifying mutations in collagen-related genes.
  • X-rays: Show characteristic bone deformities and multiple fractures.
  • Bone density testing: To assess bone strength and fragility.

Treatment

  • Bisphosphonates: To increase bone density and reduce fracture risk.
  • Physical therapy: Aimed at strengthening muscles and improving mobility.
  • Surgical interventions: Such as rodding surgery to stabilize long bones and prevent fractures.
  • Hearing aids: For patients with hearing loss.

Complications

  • Recurrent fractures: Leading to chronic pain and reduced mobility.
  • Scoliosis: Spinal deformities due to fragile vertebrae.
  • Respiratory issues: In severe cases, due to rib fractures and deformities.

Prognosis for Osteogenesis Imperfecta (OI)

  • Mild Forms (Type I): Generally, the prognosis is favorable, with most individuals having a normal life expectancy. Bone fractures may be more frequent in childhood but often decrease in adulthood. Patients typically achieve good mobility and quality of life with appropriate medical and orthopedic care.
  • Severe Forms (Type II and III): The prognosis is less favorable. Type II OI is often fatal shortly after birth due to respiratory complications and severe skeletal deformities. Type III OI patients may survive into adulthood but often experience significant physical disability, chronic pain, and respiratory problems, requiring lifelong medical management.
  • Moderate Forms (Type IV): Prognosis varies, with a higher risk of fractures and deformities. Life expectancy is generally near normal with appropriate treatment and management, but patients may require assistive devices for mobility and have ongoing musculoskeletal complications.

Rheumatoid Arthritis (RA) 

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder that primarily affects joints but can also cause significant bone destruction.

Causes and Pathophysiology

RA occurs when the immune system attacks the synovium (lining of the joints), causing inflammation and joint destruction. Over time, this leads to bone erosion and cartilage destruction.

Clinical Manifestations

The primary symptoms of RA include:

  • Joint pain: Especially in the small joints of the hands and feet.
  • Morning stiffness: Lasting longer than 30 minutes.
  • Bone erosion: As the disease progresses, bones around affected joints deteriorate.
  • Fatigue: Often accompanies other symptoms.
  • Joint deformity: Advanced RA can cause significant deformities in the joints, particularly in the fingers.

Diagnosis

  • Rheumatoid factor (RF) and anti-CCP antibodies: Commonly elevated in patients with RA.
  • X-rays: Show joint destruction, bone erosion, and soft tissue swelling.
  • MRI: Useful for detecting early bone erosion and synovitis (inflammation of the joint lining).

Treatment

  • Disease-modifying antirheumatic drugs (DMARDs): Such as methotrexate, to slow disease progression.
  • Biologic therapies: Target specific components of the immune system to reduce inflammation.
  • Steroids: To control acute flares and reduce inflammation.
  • Joint surgery: Including joint replacement, may be needed in severe cases.

Complications

  • Osteoporosis: Bone loss due to chronic inflammation and steroid use.
  • Joint deformities: Leading to disability and loss of function.
  • Bone erosion: Irreversible damage to bones around joints.

Prognosis for Rheumatoid Arthritis (RA)

  • Early Diagnosis and Treatment: With advancements in treatment, including disease-modifying antirheumatic drugs (DMARDs) and biologics, the prognosis has significantly improved. About 50-60% of patients experience remission or low disease activity if treated early and aggressively.
  • Progressive Disease: Without timely treatment, RA can lead to joint destruction, severe deformities, and disability. Approximately 40% of patients may experience significant joint damage within the first two years of disease onset.
  • Life Expectancy: RA is associated with a reduced life expectancy, often by 3-10 years, due to increased risk of cardiovascular disease, infections, and complications related to chronic inflammation. However, with appropriate management, many patients live a normal lifespan.

Fibrous Dysplasia

Fibrous Dysplasia is a rare bone disorder where normal bone and marrow are replaced with fibrous tissue, leading to bone deformities, fractures, and pain.

Causes and Pathophysiology

Fibrous dysplasia is caused by a mutation in the GNAS gene, leading to abnormal fibroblast activity. The disease can affect one bone (monostotic) or multiple bones (polyostotic).

Clinical Manifestations

Symptoms of fibrous dysplasia may include:

  • Bone pain: Often the first symptom.
  • Bone deformities: Due to abnormal bone formation.
  • Fractures: Weakened bones are prone to fractures.
  • Asymmetry of facial bones: If the skull is involved.

Diagnosis

  • X-rays: Show characteristic “ground glass” appearance of affected bones.
  • Bone scan: To assess the extent of bone involvement.
  • Biopsy: Confirms the diagnosis by demonstrating fibrous tissue in the bone.

Treatment

  • Bisphosphonates: Used to reduce bone pain and prevent fractures.
  • Surgical correction: For severe deformities or recurrent fractures.
  • Pain management: Including NSAIDs and physical therapy.

Complications

  • Fractures: Common due to bone fragility.
  • Bone deformities: Particularly in the skull and long bones.
  • Malignant transformation: Rarely, fibrous dysplasia can progress to osteosarcoma.

Prognosis for Fibrous Dysplasia

  • Monostotic Disease: Generally favorable, with fewer complications. Bone pain and fractures are manageable, and most patients have a normal lifespan.
  • Polyostotic Disease: Higher risk of complications and deformities, particularly if the skull or facial bones are affected. There is a rare risk of malignant transformation, occurring in less than 1% of cases.

Hyperparathyroidism and Bone Disease

Hyperparathyroidism occurs when excessive parathyroid hormone (PTH) is produced, leading to increased bone resorption and weakening of the bones, a condition known as osteitis fibrosa cystica.

Causes and Pathophysiology

Primary hyperparathyroidism is usually caused by a benign tumor (adenoma) of the parathyroid glands. Secondary hyperparathyroidism occurs in response to chronic kidney disease or vitamin D deficiency.

Clinical Manifestations

Symptoms of bone involvement in hyperparathyroidism include:

  • Bone pain: Due to increased bone resorption.
  • Fractures: Fragile bones are prone to breaks.
  • Muscle weakness: Due to the effects of elevated calcium levels.
  • Kidney stones: Due to high calcium levels in the blood.

Diagnosis

  • Serum calcium and PTH levels: Elevated in primary hyperparathyroidism.
  • Bone X-rays: May show bone thinning or cystic bone lesions.
  • DEXA scan: Measures bone density and helps assess fracture risk.

Treatment

  • Parathyroidectomy: Surgical removal of the overactive gland is the definitive treatment for primary hyperparathyroidism.
  • Medications: Including bisphosphonates and calcimimetics to reduce bone resorption.

Complications

  • Fractures: Due to weakened bones.
  • Osteoporosis: Progressive bone loss.
  • Kidney stones: Leading to chronic kidney damage.

Prognosis for Hyperparathyroidism and Bone Disease

  • Primary Hyperparathyroidism: Generally good with early diagnosis and surgical treatment, which often leads to the resolution of bone-related complications. Bone density typically improves within a year after surgery.
  • Untreated or Severe Cases: May lead to significant bone loss, fractures, and chronic skeletal pain. Long-term complications include osteoporosis and an increased risk of fractures if the condition is not adequately managed.

Bone Tumors (Primary and Secondary)

Bone tumors can be either primary (originating in the bone) or secondary (metastatic from another part of the body). Primary bone tumors can be benign or malignant, whereas secondary bone tumors are always metastatic.

Primary Bone Tumors

Primary bone tumors originate directly within the bone and can be either benign (non-cancerous) or malignant (cancerous). 

Tumor TypeDescription
OsteosarcomaThe most common primary malignant bone tumor, often occurring in teenagers and young adults.
ChondrosarcomaA malignant tumor of cartilage-producing cells, more commonly seen in adults.
Ewing SarcomaA highly aggressive tumor often found in children and teenagers, typically in the long bones or pelvis.
Benign TumorsIncludes osteochondroma, giant cell tumor, and enchondroma, which generally do not metastasize but may cause local bone damage.

Causes and Risk Factors

The exact cause of primary bone tumors is often unknown, but several risk factors may increase the likelihood of development:

  • Genetic mutations: Inherited syndromes such as Li-Fraumeni syndrome and retinoblastoma.
  • Previous radiation exposure: A history of radiation therapy increases the risk of bone cancer.
  • Paget’s disease of bone: In rare cases, Paget’s disease can develop into osteosarcoma.

Clinical Manifestations

  • Bone pain: Often the earliest symptom, persistent and worsening over time.
  • Swelling or a mass: Near the affected bone.
  • Fractures: Bones weakened by the tumor may break easily.
  • Systemic symptoms: Including weight loss, fever, and fatigue in more advanced cases.

Diagnosis

  • X-rays: Initial imaging to detect abnormal bone growth.
  • CT or MRI scans: Provide detailed images of the bone and surrounding soft tissues.
  • Bone biopsy: Required for definitive diagnosis to distinguish between benign and malignant tumors.
  • PET scan: Helps assess for metastasis or recurrent disease.

Treatment

  • Surgical resection: The primary treatment for most bone tumors, involving the removal of the tumor with clean margins.
  • Chemotherapy: Particularly important in treating osteosarcoma and Ewing sarcoma, often given before and after surgery.
  • Radiation therapy: Used for tumors that are inoperable or to treat metastatic disease, especially in Ewing sarcoma and chondrosarcoma.

Complications

  • Metastasis: Malignant bone tumors can spread to other parts of the body, commonly to the lungs.
  • Fractures: Bone weakened by the tumor may break.
  • Recurrence: Even after treatment, bone tumors may recur, requiring close monitoring.

Prognosis for Primary Bone Tumors

  • Osteosarcoma and Ewing Sarcoma: 5-year survival rates range from 60-80% if detected early and treated aggressively with surgery and chemotherapy. Prognosis worsens significantly with metastasis, especially to the lungs.
  • Chondrosarcoma: Prognosis varies by tumor grade. Low-grade tumors have a 5-year survival rate of 80-90%, while high-grade tumors have a poorer outcome, often requiring more extensive treatment.

Secondary (Metastatic) Bone Tumors

Secondary bone tumors are cancers that have spread (metastasized) to the bone from other primary sites, such as the breast, prostate, lung, or kidney.

Tumor TypeDescription
Breast Cancer MetastasisCancer cells originating from the breast that spread to the bone, often causing osteolytic (bone-destroying) lesions.
Prostate Cancer MetastasisCancer cells from the prostate that commonly spread to the bone, typically forming osteoblastic (bone-forming) lesions.
Lung Cancer MetastasisAggressive cancer cells from the lung that metastasize to the bone, leading to a mix of osteolytic and osteoblastic lesions.
Kidney Cancer MetastasisRenal cell carcinoma cells that spread to the bone, usually causing osteolytic lesions and significant bone destruction.

Causes and Risk Factors

Secondary bone tumors arise when cancer cells from another part of the body travel through the bloodstream or lymphatic system and implant in the bone.

Clinical Manifestations

  • Bone pain: Often severe and localized to the affected area.
  • Fractures: Due to weakened bones.
  • Hypercalcemia: Elevated blood calcium levels due to bone breakdown, causing confusion, nausea, and fatigue.

Diagnosis

  • Bone scan: Detects areas of high metabolic activity in the bones, which may indicate metastasis.
  • CT or MRI: To evaluate the extent of bone involvement.
  • Biopsy: Confirms the diagnosis and identifies the primary source of cancer.

Treatment

  • Palliative care: Aimed at controlling symptoms and improving quality of life.
  • Radiation therapy: To relieve pain and prevent fractures.
  • Surgery: In some cases, to stabilize bones weakened by metastasis.
  • Systemic therapy: Includes chemotherapy, hormonal therapy (for breast and prostate cancer), and targeted therapies based on the primary cancer.

Complications

  • Pathological fractures: Bones are weakened by metastatic disease and prone to fractures.
  • Hypercalcemia: Can be life-threatening if not treated.
  • Spinal cord compression: From tumors affecting the vertebrae, leading to paralysis or loss of function.

Secondary (Metastatic) Bone Tumors

  • Overall Prognosis: Generally poor, as metastatic bone tumors indicate advanced-stage cancer. Survival depends on the primary cancer type, extent of bone involvement, and response to systemic therapy.
  • Factors Affecting Prognosis: Cancers such as breast and prostate have better outcomes due to more effective treatments, while lung and renal cancer metastases to the bone are associated with a shorter survival. Median survival rates range from 6 months to 3 years, depending on these factors.
Strona: 1 2